Last $57.32 USD
Change Today +0.32 / 0.56%
Volume 1.2M
Q On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (Q) Key Developments

Quintiles Launches New Customer Solution to Meet the Unique Needs of Emerging Biopharmaceutical Companies

Quintiles expanded its solution set with the launch of the Quintiles Emerging Biopharma Solution -- a new offering designed to meet the unique clinical development needs and goals of these companies. The Quintiles Emerging Biopharma Solution is a newly developed operating model that is aligned with customer needs within this segment and leverages Quintiles' integrated technology platforms to provide customers with real-time data access as well as a transparent view of project performance. In addition to providing a dedicated leader with emerging biopharmaceutical operations expertise, the offering includes senior-level sponsorship for each customer. This level of support provides easy access to the unique expertise and nimble operational support required by these companies. The new offering covers all therapeutic areas and adds to the proven oncology expertise of Novella Clinical -- Quintiles' oncology service provider for emerging biopharmaceutical customers that possesses unique experience serving these companies. Recognized once again this year as an industry leader in Phase I and Phase II/III research among small biopharmaceutical customers, Quintiles has applied its proven experience in working with these companies to address their specific needs in areas such as start-up, patient recruitment and trial execution as part of this new offering.

Quintiles Transnational Holdings Inc. - Analyst/Investor Day

Quintiles Transnational Holdings Inc. - Analyst/Investor Day

Quintiles Transnational Holdings Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:55 AM

Quintiles Transnational Holdings Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:55 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Thomas H. Pike, Chief Executive Officer.

Quintiles Transnational Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of 2014

Quintiles Transnational Holdings Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $1,341,030,000 compared to $1,295,680,000 a year ago. Income from operations was $141,000,000 compared to $94,897,000 a year ago. Net income was $85,110,000 compared to $38,353,000 a year ago. Net income attributable to the company was $85,120,000 compared to $38,517,000 a year ago. Diluted earnings per share were $0.64 compared to $0.30 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $114,139,000 compared to $46,719,000 a year ago. Adjusted EBITDA was $171,793,000 compared to $149,080,000 a year ago. Adjusted income from operations was $141,948,000 compared to $124,094,000 a year ago. Adjusted net income was $85,722,000 compared to $62,925,000 a year ago. Diluted adjusted earnings per share were $0.65 compared to $0.50 a year ago. For the six months, the company reported total revenues of $2,648,876,000 compared to $2,524,521,000 a year ago. Income from operations was $282,316,000 compared to $210,062,000 a year ago. Net income was $175,324,000 compared to $86,509,000 a year ago. Net income attributable to the company was $175,303,000 compared to $86,826,000 a year ago. Diluted earnings per share were $1.32 compared to $0.71 a year ago. Income before income taxes and equity in earnings of unconsolidated affiliates was $236,851,000 compared to $128,676,000 a year ago. Net cash provided by operating activities was $38,697,000 compared to $1,385,000 a year ago. Acquisition of property, equipment and software was $35,832,000 compared to $60,277,000 a year ago. Adjusted EBITDA was $343,205,000 compared to $292,078,000 a year ago. Adjusted income from operations was $284,272,000 compared to $242,452,000 a year ago. Adjusted net income was $176,666,000 compared to $120,545,000 a year ago. Diluted adjusted earnings per share were $1.33 compared to $0.98 a year ago. The company provided earnings guidance for the full year of 2014. For the period, the company increased service revenue guidance to $4.20 billion to $4.24 billion and increased diluted adjusted EPS guidance to $2.57 to $2.67 per share, representing diluted adjusted EPS growth of 22.4% to 27.1% compared to full year 2013. The annual effective income tax rate is estimated to be approximately 30%. This financial guidance is based on the actual results for the first six month period of 2014 combined with the estimates for the following six months of 2014, assuming the June foreign currency exchange rates stay in effect for the remainder of the year, and does not reflect the impact of any future equity repurchases. Diluted GAAP earnings per share expected to be between $2.49 and $2.61 per share.

Basilea Pharmaceutica AG Enters into Agreement with Quintiles for the Commercialization of Zevtera(R)/Mabelio(R) in Europe

Basilea Pharmaceutica AG reported that it has entered into an agreement with Quintiles for the commercialization of Zevtera(R)/Mabelio(R) (ceftobiprole medocaril) in Europe. Under the agreement, Quintiles will provide commercial services including a dedicated field force, medical science liaisons, and market access support in selected countries.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
Q:US $57.32 USD +0.32

Q Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $2.50 USD +0.22
View Industry Companies
 

Industry Analysis

Q

Industry Average

Valuation Q Industry Range
Price/Earnings 23.7x
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow 22.7x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.